AMERICAN CLINICAL LABORATORY ASSN for AMERICAN CLINICAL LABORATORY ASSN

Defense DEF

TRICARE rules affecting beneficiary access to clinical laboratory services, especially molecular diagnostics. H.R. 4435, the Howard P. "Buck" McKeon National Defense Authorization Act for FY 2015. S. 2410, the Carl Levin National Defense Authorization Act for FY 2015.

Contacted: Medicare Payment Advisory Commission (MedPAC); White House Office; Centers For Medicare and Medicaid Services (CMS); Office of Management & Budget (OMB); SENATE; Defense, Dept of (DOD); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Congressional Budget Office (CBO)

Bills named: S. 2410 (113th), H.R. 4435 (113th)

Health Issues HCR

Reimbursement and coverage issues related to both the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act of 2014 (P.L. 113-93, misvalued codes, pricing for molecular diagnostic tests by CMS, billing practices, and appropriate test utilization. Issues related to the draft guidance released by FDA to regulate laboratory-developed tests (LDTs). Narrowing the In-Office Ancillary Services Exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, H.R. 2914, the Promoting Integrity in Medicare Act of 2013. 21st Century Cures Initiative.

Contacted: Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); Medicare Payment Advisory Commission (MedPAC); White House Office; SENATE; Centers For Medicare and Medicaid Services (CMS); Congressional Budget Office (CBO); Defense, Dept of (DOD); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Bills named: H.R. 2914 (113th)

Medicare/Medicaid MMM

Reimbursement and coverage issues related to both the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act of 2014 (P.L. 113-93, misvalued codes, pricing for molecular diagnostic tests by CMS, billing practices, and appropriate test utilization. Issues related to the draft guidance released by FDA to regulate laboratory-developed tests (LDTs). Narrowing the In-Office Ancillary Services Exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, H.R. 2914, the Promoting Integrity in Medicare Act of 2013. 21st Century Cures Initiative.

Contacted: Congressional Budget Office (CBO); Office of Management & Budget (OMB); Food & Drug Administration (FDA); Medicare Payment Advisory Commission (MedPAC); White House Office; Defense, Dept of (DOD); SENATE; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: H.R. 2914 (113th)

Budget/Appropriations BUD

Reimbursement and coverage issues related to both the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act of 2014 (P.L. 113-93, misvalued codes, pricing for molecular diagnostic tests by CMS, billing practices, and appropriate test utilization. Issues related to the draft guidance released by FDA to regulate laboratory-developed tests (LDTs). Narrowing the In-Office Ancillary Services Exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, H.R. 2914, the Promoting Integrity in Medicare Act of 2013. 21st Century Cures Initiative.

Contacted: Defense, Dept of (DOD); Congressional Budget Office (CBO); Medicare Payment Advisory Commission (MedPAC); HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); White House Office; Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS)

Bills named: H.R. 2914 (113th)

Medical/Disease Research/Clinical Labs MED

Reimbursement and coverage issues related to both the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act of 2014 (P.L. 113-93, misvalued codes, pricing for molecular diagnostic tests by CMS, billing practices, and appropriate test utilization. Issues related to the draft guidance released by FDA to regulate laboratory-developed tests (LDTs). Narrowing the In-Office Ancillary Services Exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, H.R. 2914, the Promoting Integrity in Medicare Act of 2013. 21st Century Cures Initiative.

Contacted: SENATE; HOUSE OF REPRESENTATIVES; White House Office; Defense, Dept of (DOD); Office of Management & Budget (OMB); Congressional Budget Office (CBO); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Medicare Payment Advisory Commission (MedPAC)

Bills named: H.R. 2914 (113th)